PATENT OR NOT TO PATENT NOVARTIS CASE STUDY IN INDIA

Authors

  • Chinmaya Kumar Mohapatra

Abstract

In a limited area, the exclusive right given to the author for invention is classified as a
patent for a set period of time. Glivec (imatini mesylate), founded by Novartis pharmaceutical
company, is recommended for the chronic myeloid leukemia, one of the most common blood
cancers in Eastern countries. On 1 April 2013, the Indian Supreme Court released its final
judgment rejecting the appeal of the Swiss giant drug maker after more than ample legal
infringement concerning their patentability.For the first time in 2006, this same Indian Patent
Office rejected Glivec 's patent under Section 3(d) of the Indian Patent Act, saying it was merely
a twistable copy of an existing drug, Imatinib. Novartis has responded to the Indian government
by lodging legal challenges, but the final verdict ends the battle in April 2013. Indeed, although
the bioavailability of the drug has grown, the High Court has argued that it has not shown
improving efficiency and Glivec is not patentable

Downloads

Download data is not yet available.

Downloads

Published

2020-12-02

How to Cite

Chinmaya Kumar Mohapatra. (2020). PATENT OR NOT TO PATENT NOVARTIS CASE STUDY IN INDIA. PalArch’s Journal of Archaeology of Egypt / Egyptology, 17(6), 5331 - 5336. Retrieved from http://mail.palarch.nl/index.php/jae/article/view/1801